HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hemogenyx Pharmaceuticals is set to launch its Phase I clinical trial for HEMO-CAR-T, a promising new therapy targeting relapsed/refractory acute myeloid leukemia in adults, marking a significant milestone for the company. The trial, designed to assess safety and efficacy, will commence following anticipated approval and site initiation in November. This development reflects Hemogenyx’s commitment to offering innovative solutions for patients with limited treatment options.
For further insights into GB:HEMO stock, check out TipRanks’ Stock Analysis page.